{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:50:46Z","timestamp":1784055046761,"version":"3.55.0"},"reference-count":192,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0731"],"award-info":[{"award-number":["2024NSFSC0731"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371539"],"award-info":[{"award-number":["32371539"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2022HXFH021"],"award-info":[{"award-number":["2022HXFH021"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["32271348"],"award-info":[{"award-number":["32271348"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189550","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:56:33Z","timestamp":1770134193000},"page":"189550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan"],"prefix":"10.1016","volume":"1881","author":[{"given":"Haitong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qintong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189550_bb0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189550_bb0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189550_bb0015","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2026.189550_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189550_bb0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","article-title":"Prevalence and role of HER2 mutations in cancer","volume":"199","author":"Cocco","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0035","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0045","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0050","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0055","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/187569209790112337","article-title":"Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens","volume":"7","author":"Nahta","year":"2009","journal-title":"Curr Pharmacogenom. Person Med"},{"key":"10.1016\/j.bbcan.2026.189550_bb0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0075","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0080","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: Fam-Trastuzumab Deruxtecan-Nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0085","first-page":"2224","volume":"12","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189550_bb0090","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0095","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0100","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189550_bb0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0130","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0135","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2026.189550_bb0140","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0145","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-21-0397","article-title":"Visualization of intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0150","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0155","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-23-2581","article-title":"RAS\/RAF comutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0160","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-22-3861","article-title":"Co-clinical study of [fam-] Trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy","volume":"29","author":"Yagishita","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0165","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189550_bb0170","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0180","article-title":"Trastuzumab Deruxtecan in residual HER2-positive early breast cancer","author":"Loibl","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0185","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103207","article-title":"185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)","volume":"9","author":"Anders","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0195","author":"Tolaney","year":"2025"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189550_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0205","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0210","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0215","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189550_bb0225","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0235","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results From the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0250","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0255","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0260","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0265","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients With HER2-low-expressing advanced breast cancer: Results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105330","article-title":"Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0275","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1186\/s12885-021-08708-5","article-title":"Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review","volume":"21","author":"Hackshaw","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0280","first-page":"657","article-title":"Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases","volume":"28","author":"DeBusk","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.bbcan.2026.189550_bb0285","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57483","article-title":"Survival among patients with ERBB2-positive metastatic breast cancer and central nervous system disease","volume":"8","author":"Ferraro","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0290","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0295","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","article-title":"Preclinical and clinical efficacy of Trastuzumab deruxtecan in breast cancer brain metastases","volume":"29","author":"Kabraji","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104092","article-title":"Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis","volume":"10","author":"Bartsch","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0305","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","article-title":"377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03","volume":"34","author":"Hurvitz","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41698-025-00801-3","article-title":"Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan","volume":"9","author":"Fabi","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.bbcan.2026.189550_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102882","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and updated meta-analysis","volume":"133","author":"Michelon","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189550_bb0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0325","doi-asserted-by":"crossref","first-page":"S1100","DOI":"10.1016\/j.annonc.2022.07.1323","volume":"33","author":"Ku","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10120-024-01555-w","article-title":"Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)","volume":"28","author":"Kawakami","year":"2025","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0335","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jtho.2021.01.285","article-title":"05 trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01","volume":"16","author":"Nakagawa","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0340","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0345","series-title":"Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients (pts) with HER2-expressing Metastatic Colorectal Cancer (mCRC): Final Results from a phase 2, Multicenter, Open-label Study (DESTINY-CRC01)","author":"Yoshino","year":"2022"},{"key":"10.1016\/j.bbcan.2026.189550_bb0350","series-title":"Trastuzumab Deruxtecan (T-DXd) in Patients (pts) with HER2-overexpressing\/amplified (HER2+) Metastatic Colorectal cancer (mCRC): Primary Results from the Multicenter, Randomized, Phase 2 DESTINY-CRC02 Study","author":"Raghav","year":"2023"},{"key":"10.1016\/j.bbcan.2026.189550_bb0355","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0360","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2\u2013expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0365","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189550_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102284","article-title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","volume":"53","author":"Pourjamal","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0375","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/15384047.2016.1139248","article-title":"An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer","volume":"17","author":"Li","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0380","series-title":"Trastuzumab Deruxtecan (T-DXd) Combinations in Patients with HER2-positive Advanced or Metastatic Breast Cancer: a Phase 1b\/2, Open-label, Multicenter, Dose-finding and Dose-expansion Study (DESTINY-Breast07)","author":"Andre","year":"2021"},{"key":"10.1016\/j.bbcan.2026.189550_bb0385","series-title":"Primary Analysis from DS8201-A-U105: A Phase 1b, Two-part, Open-label Study of Trastuzumab Deruxtecan (T-DXd) with Nivolumab (nivo) in Patients (pts) with HER2-expressing Urothelial Carcinoma (UC)","author":"Galsky","year":"2022"},{"key":"10.1016\/j.bbcan.2026.189550_bb0390","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab Deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0395","article-title":"Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic hormone receptor-negative (HR\u2212), HER2-low breast cancer: updated results from BEGONIA, a phase 1b\/2 study","volume":"83","author":"Schmid","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0400","volume":"82","author":"Tolaney","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0405","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0410","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0415","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0420","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0425","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0430","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0435","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0440","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0445","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0450","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0455","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0460","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0465","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0470","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0475","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0480","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0485","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0490","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0495","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0500","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0505","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0510","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0515","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0520","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0525","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0530","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0535","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0540","author":"NIH"},{"key":"10.1016\/j.bbcan.2026.189550_bb0545","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue--mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0550","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.pmrj.2010.03.024","article-title":"Cancer-related fatigue: state of the science","volume":"2","author":"Mitchell","year":"2010","journal-title":"Pm r"},{"key":"10.1016\/j.bbcan.2026.189550_bb0555","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2018-0590","article-title":"Patient-reported toxicities during chemotherapy regimens in current clinical practice for early breast cancer","volume":"24","author":"Nyrop","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189550_bb0560","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbacli.2014.04.001","article-title":"Association of mitochondrial dysfunction and fatigue: a review of the literature","volume":"1","author":"Filler","year":"2014","journal-title":"BBA Clin."},{"key":"10.1016\/j.bbcan.2026.189550_bb0565","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11764-010-0145-7","article-title":"Predictors and course of chronic fatigue in long-term breast cancer survivors","volume":"4","author":"Reinertsen","year":"2010","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.bbcan.2026.189550_bb0570","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11764-023-01477-z","article-title":"Biological mechanisms of cancer-related fatigue in breast cancer survivors after treatment: a scoping review","volume":"19","author":"Garc\u00eda-Gonz\u00e1lez","year":"2025","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.bbcan.2026.189550_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104700","article-title":"The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy","volume":"85","author":"Kastelein","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.bbcan.2026.189550_bb0580","series-title":"NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. NCCN Guidelines Version 1.2026","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"10.1016\/j.bbcan.2026.189550_bb0585","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-026-01973-y","article-title":"Recommendations for cancer related fatigue in post-treatment survivorship care: a cross-sectional analysis of guidelines","author":"Ayoson","year":"2026","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.bbcan.2026.189550_bb0590","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bjsports-2016-096422","article-title":"Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis","volume":"52","author":"Hilfiker","year":"2018","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0595","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis","volume":"3","author":"Mustian","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbcan.2026.189550_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103373","article-title":"A systematic review of systematic reviews and pooled meta-analysis on pharmacological interventions to improve cancer-related fatigue","volume":"166","author":"Belloni","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0605","series-title":"Pooled Analysis on Characteristics of Nausea and Vomiting in Patients Receiving Trastuzumab Deruxtecan (T-DXd) in Clinical Studies","author":"Park","year":"2024"},{"key":"10.1016\/j.bbcan.2026.189550_bb0610","series-title":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis","author":"Ettinger","year":"2008"},{"key":"10.1016\/j.bbcan.2026.189550_bb0615","first-page":"53","article-title":"Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents\u2014updated MASCC\/ESMO consensus recommendation","volume":"32","author":"Jordan","year":"2024","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189550_bb0620","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","volume":"36","author":"Sakai","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0625","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab Deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bbcan.2026.189550_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0635","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","article-title":"Perivascular Niche-resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment","volume":"85","author":"Wei","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0640","doi-asserted-by":"crossref","first-page":"1718092","DOI":"10.3389\/fimmu.2025.1718092","article-title":"Neutrophils as key drivers of pulmonary fibrosis: unveiling mechanisms and therapeutic implications","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0645","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study","author":"Pistilli","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0650","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","article-title":"Patritumab deruxtecan in HR(+)HER2(-) advanced breast cancer: a phase 2 trial","volume":"31","author":"Pistilli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0655","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.bbcan.2026.189550_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103715","article-title":"Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA","volume":"9","author":"Grinshpun","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189550_bb0670","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd-related interstitial lung disease: the five \"S\" rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.bbcan.2026.189550_bb0675","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-020-01797-3","article-title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study","volume":"39","author":"Bon","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0680","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2026.189550_bb0685","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-019-0737-2","article-title":"Progress and challenges in HER2-positive gastroesophageal adenocarcinoma","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0690","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0695","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189550_bb0700","first-page":"1202","article-title":"p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2(+) breast cancer that limits trastuzumab deruxtecan efficacy","volume":"6","author":"Hu","year":"2025","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189550_bb0705","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189550_bb0710","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/1078-0432.CCR-24-3468","article-title":"Human epidermal growth factor receptor 2 loss following treatment with trastuzumab deruxtecan in patients with metastatic breast cancer","volume":"31","author":"Gouda","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0715","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/1535-7163.MCT-23-0578","article-title":"Polyploidy in cancer: causal mechanisms, cancer-specific consequences, and emerging treatments","volume":"23","author":"Conway","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0720","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/onc.2013.96","article-title":"Generation of cancer stem-like cells through the formation of polyploid giant cancer cells","volume":"33","author":"Zhang","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189550_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217900","article-title":"Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates","volume":"630","author":"Yazdi","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189550_bb0730","series-title":"Sequential Use of Antibody-drug Conjugate after Antibody-drug Conjugate for Patients with Metastatic Breast Cancer: ADC after ADC (A3) Study","author":"Abelman","year":"2023"},{"key":"10.1016\/j.bbcan.2026.189550_bb0735","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.23.02626","article-title":"Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase II basket trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0740","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189550_bb0745","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody\u2013drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0750","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/1538-7445.AM2023-383","article-title":"Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors","volume":"83","author":"Nilsson","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0755","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0760","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0765","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0770","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody\u2013drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0775","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1158\/1538-7445.AM2025-1711","article-title":"Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study","volume":"85","author":"Alkassis","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0780","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer","author":"Rampa","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101126","article-title":"crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer","volume":"77","author":"Zou","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189550_bb0790","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189550_bb0795","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0800","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1073\/pnas.1014835108","article-title":"Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients","volume":"108","author":"Scaltriti","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189550_bb0805","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/annonc\/mdy034","article-title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","volume":"29","author":"Kim","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0810","article-title":"Impact of genomic alterations on efficacy of trastuzumab deruxtecan against human epidermal growth factor receptor-2-positive advanced gastric cancer","volume":"8","author":"Yamaguchi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bbcan.2026.189550_bb0815","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM197602192940801","article-title":"Combination chemotherapy as an adjuvant treatment in operable breast cancer","volume":"294","author":"Bonadonna","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0820","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","article-title":"Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy","volume":"27","author":"Fu","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbcan.2026.189550_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150255","article-title":"3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer","volume":"725","author":"Shiraishi","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189550_bb0830","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","article-title":"A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity","volume":"153","author":"Yao","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2026.189550_bb0835","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejps.2016.08.015","article-title":"HER2-targeted antibody drug conjugates for ovarian cancer therapy","volume":"93","author":"Jiang","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bbcan.2026.189550_bb0840","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0845","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189550_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.10.009","article-title":"Efficacy and safety of Disitamab vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: an open-label, multicenter, single-arm, phase 2 trial","author":"Huang","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0855","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.bbcan.2026.189550_bb0860","article-title":"In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates","volume":"9","author":"Jackson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189550_bb0865","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1158\/1535-7163.MCT-19-0692","article-title":"Nonclinical development of next-generation site-specific HER2-targeting antibody-drug conjugate (ARX788) for breast cancer treatment","volume":"19","author":"Nagaraja Shastri","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0870","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0875","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2019.12.037","article-title":"ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer","volume":"473","author":"Barok","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189550_bb0880","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41467-025-61213-2","article-title":"Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial","volume":"16","author":"Niu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189550_bb0885","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","article-title":"ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0890","article-title":"Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma","volume":"3","author":"Zhang","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.bbcan.2026.189550_bb0895","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0900","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","article-title":"The preclinical profile of the duocarmycin-Based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers","volume":"14","author":"van der Lee","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0905","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)","volume":"43","author":"Turner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0910","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1158\/1538-7445.AM2018-3914","article-title":"ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers","volume":"78","author":"Hamblett","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0915","first-page":"4,000","article-title":"Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer","volume":"2","author":"Barnscher","year":"2023","journal-title":"Luminescence (RLU)"},{"key":"10.1016\/j.bbcan.2026.189550_bb0920","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1535-7163.MCT-19-0207","article-title":"A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine","volume":"18","author":"Le Joncour","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189550_bb0925","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS15-P4-14-28","article-title":"Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer","volume":"76","author":"Bergstrom","year":"2016","journal-title":"Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189550_bb0930","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2018.36.15_suppl.2546","article-title":"Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric tumors","volume":"36","author":"Hamilton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0935","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bbcan.2026.189550_bb0940","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2021.39.15_suppl.2549","article-title":"Preliminary results from a phase 1\/2 study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors","volume":"39","author":"Sharma","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189550_bb0945","series-title":"A phase 1\/2 Study of a first-in-human Immune-stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-expressing Solid Tumors","author":"Li","year":"2023"},{"key":"10.1016\/j.bbcan.2026.189550_bb0950","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2025.04.002","article-title":"Molecular glue meets antibody: next-generation antibody-drug conjugates","volume":"46","author":"Tao","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2026.189550_bb0955","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1538-7445.AM2022-3933","article-title":"ORM-5029: a first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer","volume":"82","author":"Palacino","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189550_bb0960","series-title":"A Phase 1, First-in-human, Open label, Escalation and Expansion Study of ORM-5029, a Highly Potent GSPT1 Degrader Targeting HER2, in Patients with HER2-expressing Advanced Solid Tumors","author":"Hurvitz","year":"2023"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:41:15Z","timestamp":1782031275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":192,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000223"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189550","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189550"}}